Comparative Pharmacology
Head-to-head clinical analysis: BOSENTAN versus OPSYNVI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BOSENTAN versus OPSYNVI.
BOSENTAN vs OPSYNVI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Endothelin receptor antagonist; blocks endothelin-1 (ET-1) from binding to ETA and ETB receptors, inhibiting vasoconstriction and proliferation.
OPSYNVI is a dual endothelin receptor antagonist (ERA) and phosphodiesterase-5 (PDE5) inhibitor. Macitentan blocks endothelin-1 (ET-1) receptors (ETA and ETB), reducing vasoconstriction and proliferation. Tadalafil inhibits PDE5, increasing cGMP levels and causing vasodilation.
62.5 mg orally twice daily for 4 weeks, then increase to maintenance dose of 125 mg twice daily.
10 mg orally once daily, in combination with tadalafil 20 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 5 hours in healthy adults, but prolonged in patients with hepatic impairment (up to 21 hours in Child-Pugh Class A and B).
Clinical Note
moderateBosentan + Digoxin
"The serum concentration of Digoxin can be decreased when it is combined with Bosentan."
Clinical Note
moderateBosentan + Digitoxin
"The serum concentration of Digitoxin can be decreased when it is combined with Bosentan."
Clinical Note
moderateBosentan + Torasemide
"Bosentan may increase the hypotensive activities of Torasemide."
Clinical Note
moderateBosentan + Estrone sulfate
Terminal elimination half-life approximately 15 hours (range 10–20 hours) in patients with pulmonary arterial hypertension; supports twice-daily dosing.
Primarily biliary excretion (≥50% as unchanged drug) with fecal elimination; renal excretion accounts for <3% of unchanged drug.
Primarily fecal (approximately 66% of absorbed dose) and renal (approximately 22% as unchanged drug and metabolites). Biliary excretion is negligible.
Category D/X
Category C
Endothelin Receptor Antagonist
Endothelin Receptor Antagonist/Phosphodiesterase-5 Inhibitor Combination (PAH)
"The serum concentration of Estrone sulfate can be decreased when it is combined with Bosentan."